{
    "nctId": "NCT02286843",
    "briefTitle": "Can HER2 Targeted PET/CT Imaging Identify Unsuspected HER2 Positive Breast Cancer Metastases, Which Are Amenable to HER2 Targeted Therapy?",
    "officialTitle": "Can HER2 Targeted PET/CT Imaging Identify Unsuspected HER2 Positive Breast Cancer Metastases, Which Are Amenable to HER2 Targeted Therapy?",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer Metastases, HER2 Positive Breast",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "DIAGNOSTIC",
    "enrollmentCount": 49,
    "primaryOutcomeMeasure": "Percentage of Patients With HER2- Primary Breast Cancer Who Develop Imagable HER2+ Metastases",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Women age \\> 18\n* Biopsy proven HER2 negative primary breast cancer and biopsy proven metastatic disease.\n* 5 or more foci of demonstrable metastases on recent imaging modalities (CT, MR, FDG PET/CT)\n* ECOG performance score of 0-2\n\nExclusion Criteria:\n\n* Life expectancy \\< 3months\n* Pregnancy or lactation\n* Patients who cannot undergo PET/CT scanning because of weight limits\n* CNS only disease on recent imaging",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}